comparemela.com
Home
Live Updates
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results : comparemela.com
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results
ROCKVILLE, Md., Jan. 08, 2024 -- MaxCyte, Inc., , a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of...
Related Keywords
United Kingdom ,
Emma Earl Freddy Crossley ,
Mary Jane Elliott ,
David Deuchler ,
Rupert Dearden ,
Maher Masoud ,
Chris Welsh ,
Panmure Gordon ,
Nasdaq ,
Exchange Commission ,
Vertex Pharmaceuticals Inc ,
Gilmartin Group ,
Twitter ,
Maxcyte Inc ,
Linkedin ,
Exchange Commission On ,
Unaudited Fourth Quarter ,
Full Year ,
Platform License ,
Cell Therapy ,
Annual Report ,
Private Securities Litigation Reform Act ,
Investor Menu ,
Cyte Contacts ,
Joint Corporate ,
Markets ,
comparemela.com © 2020. All Rights Reserved.